Post hoc analysis of the phase 3 EMBARK trial reveals over 80% of men with high-risk biochemically recurrent prostate cancer achieved full testosterone recovery after treatment suspension at 36 weeks.

LEO Pharma's revenue grew by 11% in the first nine months of 2024, with dermatology products leading the increase at 13%.

The FDA's Oncologic Drugs Advisory Committee voted 8-1 against expanding Genentech's bispecific antibody Columvi for transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.

The phase 2 Co-PSMA trial will compare 64Cu-SAR-bisPSMA PET/CT imaging to the standard 68Ga-PSMA-11 PET/CT for detecting prostate cancer recurrence.

ABK Biomedical has received FDA approval to advance its Route90 IDE study into Stage 2, following a review of safety outcomes from the initial 16 patients.

Belite Bio dosed the first patient in the Phase 2/3 DRAGON II trial of Tinlarebant for Stargardt disease, building on positive Phase 1b results.

The NETTER-2 trial demonstrated that 177Lu-dotatate significantly prolonged progression-free survival in patients with high-grade gastroenteropancreatic neuroendocrine tumors.

Tirzepatide (Zepbound) significantly reduced the risk of death or worsening heart failure in obese patients with heart failure with preserved ejection fraction.

Rigel Pharmaceuticals has announced the enrollment of the first patient in a Phase I clinical trial of fostamatinib for sickle cell disease (SCD).

Elicio Therapeutics received supportive feedback from the FDA regarding the registrational strategy for ELI-002, an investigational cancer vaccine.

ViVerita Therapeutics announced a strategic research collaboration with Boehringer Ingelheim to accelerate discovery and validation of novel therapeutic targets for cancer treatment.

Chou2 Pharma and Ethos Discovery are collaborating on a study to assess a novel cannabinoid formulation for treating idiopathic epilepsy in dogs.

Sun Pharmaceutical Industries and Philogen have successfully completed patient enrollment in the Phase III FIBROSARC trial for Soft Tissue Sarcoma, with key readouts expected between March and June 2025.

Eli Lilly's Q4 net income soared to $4.4 billion, doubling from $2.2 billion year-over-year, propelled by strong performance of Mounjaro and Zepbound in the diabetes and obesity markets.

A groundbreaking proof-of-concept study demonstrates that ulipristal acetate, combined with misoprostol, successfully terminated pregnancies in 97% of participants, offering a potential alternative to mifepristone.

Phase 2 DAVIO-2 trial demonstrates EYP-1901's non-inferiority to aflibercept in wet AMD patients, with 50% of participants requiring no supplemental injections and an 80% reduction in treatment burden.

A comprehensive meta-analysis of 243 patients demonstrates that the Tafinlar-Mekinist combination achieves significant response rates in both pediatric (53%) and adult (39%) glioma patients.

Island Pharmaceuticals has successfully completed dosing of ten subjects in the Phase 2b treatment arm of the PROTECT trial, evaluating ISLA-101 for dengue fever treatment.

Post-hoc analysis of ARASENS trial demonstrates darolutamide plus ADT and docetaxel significantly improved overall survival in both younger and older patients with metastatic hormone-sensitive prostate cancer.

Phase 3 JAVELIN Bladder 100 trial demonstrates avelumab maintenance therapy significantly extended overall survival to 20.8 months versus 14.5 months with best supportive care alone in diabetic patients with advanced urothelial carcinoma.